Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Accounts Payables: 2022-2025

Historic Accounts Payables for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $3.2 million.

  • Entrada Therapeutics' Accounts Payables rose 145.05% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 145.05%. This contributed to the annual value of $4.3 million for FY2024, which is 29.97% up from last year.
  • As of Q3 2025, Entrada Therapeutics' Accounts Payables stood at $3.2 million, which was up 70.49% from $1.9 million recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Accounts Payables peaked at $6.5 million during Q1 2023, and registered a low of $752,000 during Q3 2023.
  • Over the past 3 years, Entrada Therapeutics' median Accounts Payables value was $2.4 million (recorded in 2023), while the average stood at $2.7 million.
  • As far as peak fluctuations go, Entrada Therapeutics' Accounts Payables plummeted by 60.97% in 2024, and later surged by 145.05% in 2025.
  • Over the past 4 years, Entrada Therapeutics' Accounts Payables (Quarterly) stood at $6.0 million in 2022, then crashed by 45.29% to $3.3 million in 2023, then increased by 29.97% to $4.3 million in 2024, then soared by 145.05% to $3.2 million in 2025.
  • Its Accounts Payables was $3.2 million in Q3 2025, compared to $1.9 million in Q2 2025 and $2.2 million in Q1 2025.